and S2b were used together in the Pipeline III to generate layers. (d) The median fluorescence intensity of each staining for each layer was plotted against skin depth from superficial dermis at far left to the skin surface at far right. sb, stratum basale, sc, stratum corneum, and AU, arbitrary unit. Scale bar = 16.1 µm FIGURE S3 Quantification of TGm-1 and filaggrin expression and their colocalization. A .tif image of double IF staining of TGm-1 (red) and filaggrin (green) (a) was used to generate a ROI image (b). (a) and (b) were used together to generate a segmented image (c). The projected image of isPLA of TGm-1/filaggrin (d) was used together with its ROI image (e) to generate a segmented image (f).
| BACKGROUND
Recent research has developed and used small-animal imaging methods that have high sensitivity and resolution and that can measure living organisms at the level of cells or molecules. [1] As these non-invasive imaging technologies do not require sacrifice of the experimental animals and can verify benefits to organs, they are proposed as a main research methodology for drug development.
Reporter genes for non-invasive molecular images include bioluminescent, [2] fluorescent [3] and PET reporter gene (PRG). Nuclear medical molecular imaging technologies using PRG/PET reporter probe (PRP) systems have been actively studied. Along with reporter genes, introducing fusion genes associated with the genes of interest in such areas as cancer cell death or angiogenesis around tumors can be used to evaluate the expressions of associated genes. Studies combining optical, fluorescence and PRGs to generate complex molecular images have been carried out. [4, 5] This study transplanted melanoma cell lines with PRGs and herpes simplex virus 1-thymidine kinase (HSV1-tk) genes into mouse skin to generate a tumor. [6] We systemically administrated a reporter tracer, 9-(4-(18) Using ordered subsets expectation maximization algorithms, section images were obtained. [7] The spatial resolution of the recon- PET images, with a difference of 17.1 (P < .01). The melanoma vs. heart difference was 9.9 (P < .05), vs gall bladder was 5.1, vs intestine was 
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The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I
Abstract
In this study, we aimed to investigate the anti-melanoma effects and the JAK2/STAT3 pathway-related mechanism of action of atractyle- 
| BACKGROUND
Malignant melanoma is the most aggressive skin cancer. Although immunotherapies, chemotherapies and targeted therapies have shown encouraging clinical results in treating melanoma, the 5-year survival rate of patients with metastatic melanoma is only 17%. [1] 
